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Background: Elevated plasma B-type natriuretic peptide (BNP) levels and their association 
with heart failure have been reported in subjects with acute exacerbations of chronic obstructive 
pulmonary disease (AECOPD).
Purpose: To examine and compare plasma BNP levels and diastolic and systolic dysfunction 
in subjects with AECOPD and stable chronic obstructive pulmonary disease (COPD).
Methods: In all, 87 unselected consecutive hospitalizations due to AECOPD in 61 subjects and 
a total of 190 consecutive subjects with stable COPD were recruited. Plasma BNP levels were 
compared cross-sectionally and longitudinally. Transthoracic echocardiographic examinations 
were also performed in the hospitalized subjects.
Results: In the hospitalized subjects, the median plasma BNP level (interquartile range) was 55.4 
(26.9–129.3) pg/mL and was higher than that of patients with stable COPD: 18.3 (10.0–45.3) 
for Global Initiative for Chronic Obstructive Lung Disease grade I; 25.8 (11.0–53.7) for 
grade II; 22.1 (9.1–52.6) for grade III; and 17.2 (9.6–22.9) pg/mL for grade IV, all P,0.001. 
In 15 subjects studied prospectively, the median plasma BNP level was 19.4 (9.8–32.2) pg/mL 
before AECOPD, 72.7 (27.7–146.3) pg/mL during AECOPD, and 14.6 (12.9–39.0) pg/mL 
after AECOPD (P,0.0033 and P,0.0013, respectively). Median plasma BNP levels during 
AECOPD were significantly higher in ten unsuccessfully discharged subjects 260.5 (59.4–555.0) 
than in 48 successfully discharged subjects 48.5 (24.2–104.0) pg/mL (P=0.0066). Only 5.6% 
of AECOPD subjects were associated with systolic dysfunction defined as a left ventricular 
ejection fraction (LVEF) ,50%; a further 7.4% were considered to have impaired relaxation 
defined as an E/A wave velocity ratio ,0.8 and a deceleration time of E .240 ms. BNP levels 
were weakly correlated with the E/peak early diastolic velocity of the mitral annulus (Ea) ratio 
(Spearman’s rank correlation coefficient =0.353, P=0.018), but they were not correlated with 
the LVEF (Spearman’s rank correlation coefficient =−0.221, P=0.108).
Conclusion: A modest elevation of plasma BNP is observed during AECOPD. It appears that 
AECOPD may have an impact on plasma BNP levels that is not attributable to heart failure.
Keywords: chronic obstructive pulmonary disease, acute exacerbations of chronic obstructive 
pulmonary disease, B-type natriuretic peptide, heart failure
Introduction
Acute exacerbation of chronic obstructive pulmonary disease (AECOPD) is a com-
mon cause of acute hospitalization1,2 and a great risk for morbidity and mortality. 
Since chronic obstructive pulmonary disease (COPD) is considered to be a systemic 
disorder, it has been reported that one of its multiple aspects is cardiovascular in 
nature. Although various cardiac diseases, including acute myocardial infarction3–5 
and chronic heart failure (HF),6–17 may be associated with AECOPD, the typical 
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 presentation of a specific cardiac condition is rather excep-
tional in clinical practice.
The B-type natriuretic peptide (BNP) levels in the 
blood, which are used for the screening and diagnosis of 
acute decompensated HF,18,19 are also typically increased in 
patients with asymptomatic or symptomatic left ventricular 
dysfunction. It has also been reported that it is possible to 
recognize heart failure in elderly patients with stable COPD 
in primary care,20 and that BNP can be used to differentiate 
HF from respiratory diseases, including COPD, in patients 
with dyspnea,21–24 although there is no level of BNP that per-
fectly differentiates patients with and without HF. The Task 
Force for the Diagnosis and Treatment of Acute and Chronic 
Heart Failure 2008 of the European Society of Cardiology 
also reported that an evaluation of natriuretic peptide (BNP 
or N-terminal pro-brain natriuretic peptide [NT-proBNP]) 
levels may be helpful in this population, but the results are 
often preliminary.25
Bozkanat et al first reported that COPD patients had 
higher levels of BNP as compared to controls, and that BNP 
determination has a role in the diagnosis of cor pulmonale 
in patients with COPD.26 Abroug et al demonstrated that 
NT-proBNP is useful for excluding AECOPD associated 
with left ventricular dysfunction, since left-heart involve-
ment in AECOPD was the only variable independently 
associated with the increased secretion of NT-proBNP.27 
Inoue et al also reported elevated plasma BNP levels and 
a significant correlation with the percentage of  ejection 
fraction and pulmonary artery systolic pressure in 
COPD.28 These authors appeared to consider that the high 
levels of BNP may be related to classical left ventricular 
dysfunction.
Abroug et al demonstrated that diastolic dysfunction 
was more frequent than systolic dysfunction in patients with 
AECOPD.27 Abusaid et al also reported that the diastolic 
dysfunction of the left ventricle in transthoracic echocar-
diography is common in subjects with AECOPD and may be 
associated with an increased frequency of hospitalization.29 
On the other hand, Iwanaga et al reported that the plasma 
BNP levels reflect left ventricular end-diastolic wall stress 
more than any other parameter in systolic and diastolic HF, 
and that in a comparison between systolic and diastolic HF, 
the BNP level was significantly higher in systolic HF since 
the end-diastolic wall stress was also significantly higher in 
systolic than in diastolic HF.30 Therefore, we hypothesized 
that diastolic or systolic dysfunction could be detected using 
plasma BNP levels in subjects with AECOPD. The purpose 
of the present study was to evaluate diastolic and systolic 
dysfunction in subjects with AECOPD and stable COPD, 
mainly using the plasma levels of BNP.
Methods
subjects
A total of 87 unselected consecutive hospitalizations due to 
AECOPD in 61 subjects were recruited from the Respira-
tory Division of the Kyoto-Katsura Hospital in Kyoto, Japan, 
a general hospital that provides health care mainly for the 
western part of the city of Kyoto. The subjects were hospi-
talized and treated for AECOPD between October 2006 and 
July 2008. All subjects were evaluated and treated based on 
the clinical pathway for AECOPD.31 Therefore, the inclusion 
and exclusion criteria were identical to the clinical pathway 
for AECOPD that has been described elsewhere.31 Briefly, the 
inclusion criteria were: 1) a clinical diagnosis of COPD; 2) 
age over 40 years; 3) a history of smoking (10 pack-years or 
greater); 4) a forced expiratory volume in 1 second (FEV
1
)/
forced vital capacity (FVC) ,0.7 on or before the first day 
of admission; 5) the absence of previous inflammatory 
changes on chest radiographs that influenced pulmonary 
function (for example, a previous thoracoplasty or tubercular 
sequelae); and 6) the presence of aggravated symptoms of 
COPD compatible with exacerbations. The exclusion criteria 
included intubation on the first day of admission, noninfec-
tive exacerbations including episodes due to pneumothorax 
or cardiac failure without AECOPD, and clinically relevant 
cardiac valvular disease.
Since it is believed that the therapeutic management 
of AECOPD with no clinical signs of pneumonia should 
be the same as for an exacerbation of COPD as a result of 
pneumonia,32 we included patients with COPD complicated 
by pneumonia. Most patients with a predominant clinical 
diagnosis of HF were admitted to the cardiac division, and 
thus they were not included in this present study.
In addition, 190 consecutive subjects with stable COPD 
were also recruited from the outpatient clinic of the Respi-
ratory Division of the Kyoto-Katsura Hospital between 
September 2006 and August 2008. The entry criteria for 
stable COPD included: 1) a diagnosis of COPD; 2) age over 
40 years; 3) a history of smoking; 4) a FEV
1
/FVC ,0.7; 
5) regular attendance in the clinic for more than 6 months 
to avoid substantial changes brought about by new medical 
interventions; and 6) no changes in the treatment regimen for 
more than 4 weeks. Subjects with any history suggestive of 
asthma, an exacerbation of their COPD over the preceding 
8 weeks, previous inflammatory changes revealed on chest 
radiographs that influenced pulmonary function (for example, 
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a previous thoracoplasty or tubercular sequelae), or any other 
illness, were excluded. In addition, 43 patients were included 
in both the AECOPD group and in the stable phase.
Measurements
All AECOPD subjects who were hospitalized during this 
study period were evaluated and treated based on the clinical 
pathway for AECOPD. Regardless of whether the  treatment 
was completed based on the clinical pathway or they later 
dropped out, the clinical pathway was used to evaluate the sub-
jects immediately after seeing them. The details of this clinical 
pathway for AECOPD have been described elsewhere.31
Blood samples were obtained at the initial examination, 
and plasma BNP levels were measured by chemiluminescent 
enzyme immunoassay. Chest radiographs were obtained 
before admission in all subjects. Pulmonary function tests 
were performed after the inhalation of 200 µg of salbutamol 
using a metered-dose inhaler with a spacer on the day after the 
completion of a 10–14 day oral course of glucocorticoster-
oids, or before discharge. According to the method described 
by the American Thoracic Society/European Respiratory 
Society Task Force in 2005,33 three acceptable spirometric 
flow–volume curves were recorded with the patient sitting 
using a calibrated 2.0 L syringe before every measurement. 
The highest FEV
1
 and the highest FVC values among three 
maneuvers were then analyzed. The predicted values for the 
FEV
1
 and vital capacity were calculated according to the pro-
posal from the Japan Society of Chest Diseases.34 The residual 
volume was measured by the closed-circuit helium method, 
and the diffusion capacity for carbon monoxide (DLco) was 
measured using the single-breath technique (CHESTAC-65V; 
Chest MI Inc., Tokyo, Japan). The outcome at 30 days after 
discharge from hospitalization with AECOPD was then 
analyzed. Successfully discharged subjects were defined as 
those who were alive without readmission at 30 days after 
discharge; unsuccessfully discharged subjects were defined 
as those who were readmitted within 30 days after discharge, 
died during hospitalization, or moved to another hospital for 
more intensive treatment.
As many patients with AECOPD as possible underwent 
transthoracic echocardiographic examinations on the first 
day of their admission. The echocardiographic recordings 
included Doppler analysis, and two-dimensional views that 
made it possible to determine the left ventricular ejection 
fraction (LVEF). Additional recordings enabling the assess-
ment of diastolic functional indices using Doppler echocar-
diography (mitral flow and pulmonary venous flow) were 
performed where possible. From the mitral inflow profile, 
the E- and A-wave velocity and the deceleration time of the 
E wave (DTE) were measured, and the E/A velocity ratio 
was calculated. The flow velocities of the left or right upper 
pulmonary veins were recorded, and the ratio of the systolic 
to diastolic forward flow (S/D ratio) was calculated. Since 
the peak early diastolic velocity of the mitral annulus (Ea) 
was recorded, the ratio of the early transmitral velocity to the 
tissue Doppler mitral annular early diastolic velocity (E/Ea 
ratio) was also calculated. For this study, systolic dysfunction 
was defined as an ejection fraction of ,50%. For diastolic 
dysfunction, impaired relaxation was defined as an E/A 
ratio ,0.8, a DTE .240 ms and when an isovolumic relax-
ation time (IVRT) measurement was available, an IVRT .90 
ms.27 A restrictive pattern was defined as an E/A ratio of 1.5 
or more, a DTE ,160 ms, and when an IVRT was available, 
an IVRT ,70 ms.27
All eligible subjects with stable COPD underwent the 
following examinations on the same day: pulmonary func-
tion tests; arterial blood gas analysis; chest radiography; and 
measurements of plasma BNP levels. This measurement of 
plasma BNP levels was repeated every 6 months throughout 
the study period. The study was approved by the Ethics Com-
mittee of the Kyoto-Katsura Hospital.
Statistical analysis
All results are expressed as means ± standard deviation, 
or medians (interquartile range) for BNP levels as their 
distributions were nonnormal, unless otherwise stated. 
Mann–Whitney U tests were used to compare BNP levels 
between subjects first hospitalized with AECOPD and 
subjects with stable COPD, and between successfully and 
unsuccessfully discharged subjects. The significance of 
the intergroup differences based on the Global Initiative 
for Chronic Obstructive Lung Disease (GOLD) grades or 
study periods (before AECOPD, during AECOPD, and after 
AECOPD) was determined by an analysis of variance. When 
a significant difference was observed, Fisher’s protected least 
significant difference method was used to identify where the 
differences occurred. The relationships between two sets of 
data were analyzed by Spearman’s rank correlation tests. 
Unpaired Student’s t-tests or chi-square tests were then used 
to compare values between groups. A P-value ,0.05 was 
considered to be statistically significant.
Results
Demographics
During the study period, 87 hospitalizations in the 61 
subjects were identified. In addition, 43 subjects were 
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Table 1 Demographic details and outcomes for 61 subjects first 
hospitalized during the study period with acute exacerbations of 
chronic obstructive pulmonary disease
N Mean ± SD  
or N (%)
age (years) 61 75.4±7.6
sex (male) 61 49 (80.3%)
history of smoking (pack-years) 61 76±41
Body mass index (kg/m2) 58 20.1±3.3
Pneumonia as a complication (present) 61 25 (41.0%)
arterial blood gas at the beginning of the treatment with variable 
concentration of oxygen
 PaO2 (mmhg) 61 61.5±21.3
 PaCO2 (mmhg) 61 46.4±18.5
 ph 61 7.410±0.079
B-type natriuretic peptide (pg/ml) 61 126.8a±177.5
Management during the hospitalization
 Oxygen administration 61 51 (83.6%)
 noninvasive positive pressure ventilation 61 23 (37.7%)
 Mechanical ventilation with intubation 61 1 (1.6%)
Pulmonary function tests after treatment
 sVC (% predicted) 58 82.7±24.1
 FVC (% predicted) 58 81.0±22.8
 FeV1 (% predicted) 58 56.0±23.8
 FeV1/FVC (%) 58 45.2±14.4
 TlC (% predicted) 55 102.0±20.6
 DlCO (ml/min/mmhg) 47 6.79±3.83
 DlCO (% predicted) 47 48.8±22.0
 DlCO/Va (ml/min/mmhg/l) 47 1.86±1.06
length of stay (days) 82 21.5±24.6
readmission within 30 days, number (%) 54 6 (11.1%)
Mortality within hospitalization, number (%) 59 2 (3.4%)
Mortality within 30 days, number (%) 59 2 (3.4%)
Mortality within 90 days, number (%) 58 3 (5.2%)
Note: aMedian (interquartile range) 55.4 (26.9–129.3).
Abbreviations: sD, standard deviation; PaO2, partial pressure of oxygen in arterial 
blood; PaCO2, partial pressure of carbon dioxide in arterial blood; sVC, slow vital 
capacity; FVC, forced vital capacity; FeV1, forced expiratory volume in 1 second; TlC, 
total lung capacity; DlCO, diffusion capacity for carbon monoxide; DlCO/Va, diffusion 
capacity for carbon monoxide/alveolar volume.
hospitalized only once due to AECOPD during the study 
period, and 12 subjects were hospitalized twice. Four 
subjects were hospitalized three times; two patients were 
hospitalized four times. Spirometry was performed in 
81 out of 87 episodes before discharge or after completing 
oral corticosteroids for 10–14 days. The average age of the 
61 subjects at their initial hospitalization was 75.4 years 
(Table 1). In 58 out of 61 subjects, the average postbron-
chodilator FEV
1
 was 1.07 L (56.0% predicted), and the 
FEV
1
/FVC was 45.2% (Table 1). In the other three subjects, 
spirometric results performed prior to admission were used. 
According to the grading of the severity of the airflow limi-
tation in COPD described in the GOLD document,2 there 
were eleven (18.0%), 22 (36.1%), 20 (32.8%), and eight 
(13.1%) subjects, respectively, at grades I, II, III, and IV. 
In 25 patients (41.0%), chest radiographs revealed infiltra-
tion compatible with pneumonia.
Plasma BnP levels
The median plasma BNP level was 55.4 (26.9–129.3) pg/mL 
at the first hospitalization with AECOPD during the study 
period, and in the stable patients, it was 21.5 (10.3–47.5) pg/mL 
(Table 2). This difference was statistically significant at 
P,0.0001. On the other hand, for stable COPD, median 
plasma BNP levels did not differ significantly (P=0.53) 
across GOLD grades: 18.3 (10.0–45.3) for GOLD grade I, 
25.8 (11.0–53.7) for grade II, 22.1 (9.1–52.6) for grade III, 
and 17.2 (9.6–22.9) pg/mL for grade IV (Figure 1).
Since the measurement of plasma BNP levels was per-
formed every 6 months, the plasma BNP levels had been 
measured within 1 month before admission in 15 subjects 
(Figure 2), in whom the plasma BNP levels changed signifi-
cantly (P=0.002). Before admission, the plasma BNP level 
was 19.4 (9.8–32.2) pg/mL, and rose to 72.7 (27.7–146.3) 
pg/mL during AECOPD (P=0.0033), and then fell over 
a month from exacerbation to 14.6 (12.9–39.0) pg/mL 
(P=0.0013). The pre- and post-values were not statistically 
different (P=0.75).
Following the f irst hospitalization with AECOPD, 
there were 48 successfully discharged subjects 
Table 2 Demographic details of 190 subjects with stable chronic 
obstructive pulmonary disease
Mean SD Maximum Minimum
age (years) 71.7 8.7 96.0 40.0
BMI (kg/m2) 21.9 3.2 31.6 13.9
Cumulative smoking  
(pack-years)
71 42 268 4
sVC (% predicted) 99.8 22.8 154.0 42.6
FVC (% predicted) 95.6 23.1 148.5 40.0
FeV1 (% predicted) 66.6 27.4 133.0 13.0
FeV1/FVC (%) 47.5 13.5 69.9 21.4
TlC (% predicted) 108.5 16.8 160.6 68.8
Dlco
a (% predicted) 62.4 28.7 174.7 2.5
PaO2
b (mmhg) 78.5 11.7 105.5 49.2
PaCO2
b (mmhg) 39.8 5.3 57.7 29.3
ph (arterial blood)b 7.433 0.027 7.511 7.337
BnP (pg/ml) 51.8c 111.5 1,180.0 3.9
sex 166 male/24 female
smoking history 32 current/158 former
Notes: an=187; boxygen administered in six subjects; three subjects received 
noninvasive positive pressure ventilation at home; cmedian (interquartile range) 
21.5 (10.3–47.5).
Abbreviations: sD, standard deviation; BMI, body mass index; sVC, slow vital 
capacity; FVC, forced vital capacity; FeV1, forced expiratory volume in 1 second; 
TlC, total lung capacity; DlCO, diffusion capacity for carbon monoxide; PaO2, partial 
pressure of oxygen in arterial blood; PaCO2, partial pressure of carbon dioxide in 
arterial blood; BnP, B-type natriuretic peptide; ph, power of hydrogen.
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Figure 1 Cross-sectional comparisons of plasma BnP levels (means ± standard 
deviation) in 61 subjects first hospitalized with AECOPD, in 65 subjects at GOLD 
grade I with stable COPD, in 65 subjects at grade II, in 40 subjects at grade III, and 
in 20 subjects at grade IV.
Notes: Plasma BnP levels were not statistically different among the gOlD grades 
(P=0.53), but the plasma BNP levels measured in 61 subjects first hospitalized with 
aeCOPD were statistically higher than in subjects with stable COPD at each gOlD 
grade (P,0.001).
Abbreviations: aeCOPD, acute exacerbations of chronic obstructive pulmonary 
disease; COPD, chronic obstructive pulmonary disease; BnP, B-type natriuretic 
peptide; gOlD, global Initiative for Chronic Obstructive lung Disease.
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Figure 2 longitudinal comparisons of plasma BnP levels in 15 subjects before aeCOPD, during aeCOPD and after aeCOPD.
Note: Bars indicate standard errors.
Abbreviations: aeCOPD, acute exacerbations of chronic obstructive pulmonary disease; BnP, B-type natriuretic peptide.
(hospitalization length, 19±20 days). There were ten unsuc-
cessfully  discharged subjects, including six who were 
readmitted within 30 days after discharge, two who died 
during hospitalization, and two who moved to another 
hospital for more intensive care. Three patients could not 
be  followed after discharge and were excluded from the 
analysis. Median plasma BNP levels during AECOPD were 
 significantly higher in the ten  unsuccessfully discharged 
 subjects (260.5 [59.4–555.0] pg/mL) than in those discharged 
 successfully, (48.5 [24.2–104.0] pg/mL, P=0.0066).
echocardiography
Transthoracic echocardiograms were examined in 
54 patients. The average value for the LVEF was 69% and 
was under 50% in three episodes (5.6%) (Table 3). In terms 
of diastolic function, the E/A velocity ratio was determined 
in 38 subjects and was found to be ,0.8 (63.2%). The DTE 
was .240 ms in six (13.0%) out of the 46 patients studied. 
The S/D ratio was below 1.0 in four (28.6%) out of 14 patients 
in whom this measurement could be  collected. The E/Ea 
ratio was 15.0 or more in four (9.3%) out of 43 subjects 
without systolic dysfunction. Using those criteria, only four 
subjects (7.4%) were considered to show impaired relaxation. 
A restrictive pattern of left ventricular (LV) function was 
never observed. The Spearman’s rank correlation coefficients 
(Rs) between the plasma BNP levels and the systolic and 
diastolic functional indices are also listed in Table 3. BNP 
levels were weakly correlated with the E/Ea ratio (Rs=0.353, 
P=0.018), but they were not correlated with the LVEF 
(Rs=−0.221, P=0.108).
Discussion
This report confirms previous observations that plasma BNP 
levels are slightly but significantly elevated during AECOPD 
in most subjects with COPD, although the BNP levels 
varied quite widely between subjects with stable COPD, 
and that BNP rises during an exacerbation, and then returns 
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Table 3 Transthoracic echocardiographic findings and correlation with plasma BNP levels in 61 subjects with acute exacerbation 
of COPD
Number Mean Median SD Maximum Minimum Correlation  
with BNP
Rs P-value
laD (mm) 53 31 29 10 83 19 0.054 0.696
IVsT (mm) 54 9 9 1 12 6 −0.023 0.868
lVPWth (mm) 54 9 9 1 12 6 −0.003 0.981
lVDd (mm) 54 44 44 6 60 31 0.332 0.016
lVDs (mm) 54 27 27 6 47 18 0.283 0.039
eDV (ml) 54 91 87 29 182 37 0.331 0.016
esV (ml) 53 29 26 17 104 9 0.284 0.041
eF (%) 54 69 71 10 83 32 −0.221 0.108
Fs (%) 54 39 40 7 52 14 −0.141 0.303
sV (ml) 54 61 62 18 103 25 0.244 0.075
CO (l/min) 46 5.25 5.12 1.37 8.60 2.80 0.038 0.797
e-wave velocity (m/sec) 50 0.67 0.63 0.32 1.67 0.29 0.299 0.036
a-wave velocity (m/sec) 43 0.82 0.80 0.24 1.30 0.34 −0.072 0.641
e/a ratio 41 0.74 0.74 0.23 1.23 0.35 0.156 0.325
Deceleration time of the e wave (DTe) (msec) 48 181 180 72 383 58 −0.205 0.160
s/D ratio 16 1.25 1.29 0.34 1.83 0.79 −0.278 0.281
ea velocity (m/sec) 47 0.09 0.07 0.15 1.10 0.03 −0.172 0.243
e/ea ratio 46 10.47 9.40 5.80 32.75 3.91 0.353 0.018
Note: Rs, Spearman’s rank correlation coefficients.
Abbreviations: COPD, chronic obstructive pulmonary disease; sD, standard deviation; BnP, B-type natriuretic peptide; laD, left atrial dimension; IVsT, interventricular 
septum thickness; lVPWth, left ventricular posterior wall thickness; lVDd, left ventricular end-diastolic dimension; lVDs, left ventricular internal dimension in systole; 
eDV, end-diastolic volume; esV, end-systolic volume; eF, ejection fraction; Fs, fractional shortening; sV, stroke volume; CO, cardiac output; s/D ratio, ratio of systolic to 
diastolic forward flow; Ea, peak early diastolic velocity of the mitral annulus.
to the baseline level on recovery.28,35 This demonstrates 
that the elevated BNP levels are related in some way to the 
exacerbation. Despite this elevation of BNP, we showed that 
cardiac systolic and diastolic dysfunction was present in only 
a small number of episodes with AECOPD.
It has been reported since the 1990s that the prevalence 
of COPD ranges from 10%–32% in patients with chronic 
heart failure.7–11 Coexisting LV dysfunction was observed 
in 32% of patients with COPD presenting with symptomatic 
deterioration.6 Rutten et al reported that approximately 30% 
of patients with stable COPD have some degree of HF.20 
However, after the concept of diastolic dysfunction became 
widely appreciated, it was then reported that heart failure was 
mainly due to diastolic dysfunction, especially in subjects with 
COPD.36,37 Abroug et al examined 148 patients admitted to 
the intensive care unit for AECOPD and found systolic dys-
function in 11.5%, diastolic dysfunction in 32.4%, and both 
in 6.8% of the patients using the same criteria of systolic and 
diastolic dysfunction employed in the present study.27 Abusaid 
et al also reported that diastolic dysfunction was observed in 
60.4% of 139 patients hospitalized for AECOPD, although 
they did not provide specific criteria for the diagnosis.29
As compared with previous reports, the prevalence of 
LV failure was low in our study. There is no doubt that the 
prevalence of diastolic dysfunction will be determined by 
the definition of diastolic dysfunction that was used. In the 
present study, using the sole criterion of an E/A ratio ,1.0, 
diastolic dysfunction would be found in 90% of cases. 
 However, we reanalyzed our data using the same criteria for 
diastolic dysfunction as Abroug.27 Despite this, the prevalence 
of diastolic dysfunction was still very different from the 
Abroug report. One possible reason may be that the patients 
included in Abroug’s study had more severe AECOPD, since 
they had been admitted to an intensive care unit, presumably 
because of respiratory failure.
It has been reported that the elevated levels of NT-proBNP 
are one of the mortality predictors among patients admitted to 
the hospital with AECOPD, although the pathophysiological 
basis for this is unknown.38–40 The present study also con-
firmed that the plasma BNP levels during AECOPD may be 
an important determinant of successful discharge.
In our study, although AECOPD appeared to have had 
little impact on cardiac function, plasma BNP levels were 
elevated. There are at least two possible mechanisms for 
this rise. First, pulmonary hyperinflation has the potential 
for significant adverse effects on cardiovascular function in 
COPD,41 and AECOPD is characterized by worsening lung 
hyperinflation.42 It is possible that BNP was released from the 
International Journal of COPD 2014:9 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
161
Plasma levels of BnP and acute exacerbations of COPD
heart as a result of this, rather than as a direct effect of intrin-
sic myocardial function. Second, BNP may reflect systemic 
or lung inflammation during AECOPD that is qualitatively or 
quantitatively different from stable COPD.43 This modifica-
tion of inflammation may be related to LV preload through 
systemic vasoconstriction, or alternatively lung hyperinflation 
or inflammation may be causing the increase in BNP levels 
via an increase in left ventricular wall stress.
This single-center study was limited by the number of 
patients with AECOPD admitted to the study site and does 
include all the patients with AECOPD and stable COPD 
seen in this hospital during the 22-month study period. Some 
measurements were not completed during echocardiography 
since it was difficult to obtain all of the echocardiographic 
measurements, especially in patients with COPD because of 
their hyperinflation. The fact that the E/A ratio was obtained 
in only 41 out of 54 patients might have introduced some 
bias in the proportion of patients with a final diagnosis of 
diastolic dysfunction. Unfortunately, we do not have a record 
of whether the patients were in atrial fibrillation at the time 
of presentation, or had reduced creatinine clearance, both of 
which are known to raise BNP levels. Patients with stable 
COPD did not undergo transthoracic echocardiographic 
examinations, but we do not see this to be a major limita-
tion, since the focus of our interest was on AECOPD, not 
the stable state.
Conclusion
Plasma BNP levels were slightly but significantly elevated 
during AECOPD in most subjects with COPD, although a 
wide range of BNP levels were seen in subjects with stable 
COPD. Echocardiographic examinations indicated cardiac 
systolic and diastolic dysfunction in only a small number of 
patients during the AECOPD.
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